Pigmentation Disorder Treatment Market By Type, By Treatment, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market
3.7. Patent Landscape

CHAPTER 4: PIGMENTATION DISORDER TREATMENT MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Vitiligo
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.2.4 Vitiligo Pigmentation Disorder Treatment Market by Type
4.2.4.1 Segmental Market size and forecast, by region
4.2.4.2 Non-segmental Market size and forecast, by region
4.3 Melasma
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Others
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country

CHAPTER 5: PIGMENTATION DISORDER TREATMENT MARKET, BY TREATMENT
5.1 Overview
5.1.1 Market size and forecast
5.2 Corticosteroids
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Calcineurin inhibitor
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Others
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country

CHAPTER 6: PIGMENTATION DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Drug store and retail pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Online pharmacies
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country

CHAPTER 7: PIGMENTATION DISORDER TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.2.1 North America Vitiligo Pigmentation Disorder Treatment Market by Type
7.2.3 North America Market size and forecast, by Treatment
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U. S.
7.2.5.1.1 Market size and forecast, by Type
7.2.5.1.2 Market size and forecast, by Treatment
7.2.5.1.3 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Type
7.2.5.2.2 Market size and forecast, by Treatment
7.2.5.2.3 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Type
7.2.5.3.2 Market size and forecast, by Treatment
7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.2.1 Europe Vitiligo Pigmentation Disorder Treatment Market by Type
7.3.3 Europe Market size and forecast, by Treatment
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Type
7.3.5.1.2 Market size and forecast, by Treatment
7.3.5.1.3 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Type
7.3.5.2.2 Market size and forecast, by Treatment
7.3.5.2.3 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Type
7.3.5.3.2 Market size and forecast, by Treatment
7.3.5.3.3 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Type
7.3.5.4.2 Market size and forecast, by Treatment
7.3.5.4.3 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Type
7.3.5.5.2 Market size and forecast, by Treatment
7.3.5.5.3 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Type
7.3.5.6.2 Market size and forecast, by Treatment
7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.2.1 Asia-Pacific Vitiligo Pigmentation Disorder Treatment Market by Type
7.4.3 Asia-Pacific Market size and forecast, by Treatment
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Type
7.4.5.1.2 Market size and forecast, by Treatment
7.4.5.1.3 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Type
7.4.5.2.2 Market size and forecast, by Treatment
7.4.5.2.3 Market size and forecast, by Distribution Channel
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by Type
7.4.5.3.2 Market size and forecast, by Treatment
7.4.5.3.3 Market size and forecast, by Distribution Channel
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by Type
7.4.5.4.2 Market size and forecast, by Treatment
7.4.5.4.3 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Type
7.4.5.5.2 Market size and forecast, by Treatment
7.4.5.5.3 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Type
7.4.5.6.2 Market size and forecast, by Treatment
7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.2.1 LAMEA Vitiligo Pigmentation Disorder Treatment Market by Type
7.5.3 LAMEA Market size and forecast, by Treatment
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Type
7.5.5.1.2 Market size and forecast, by Treatment
7.5.5.1.3 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Type
7.5.5.2.2 Market size and forecast, by Treatment
7.5.5.2.3 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Type
7.5.5.3.2 Market size and forecast, by Treatment
7.5.5.3.3 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Type
7.5.5.4.2 Market size and forecast, by Treatment
7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Players
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES
9.1 Arcutis Biotherapeutics
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Astellas Pharma Inc.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Bausch Health Companies Inc
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Incyte Corporation
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Dermavant Science Inc.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Viatirs Inc. (Mylan N. V.)
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Galderma SA
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Obagi Cosmeceuticals LLC
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Dr. Reddy's Laboratories Limited
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Glenmark Pharmaceuticals Ltd
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

Executive Summary

According to this report, titled, 'Pigmentation Disorder Treatment Market,' The pigmentation disorder treatment market was valued at $799.79 million in 2021, and is estimated to reach $1,220.91 million by 2031, growing at a CAGR of 4.3% from 2022 to 2031.

Pigmentation disorders are irregularities in the skin's tissues that can be identified, examined for, and treated in primary care settings. As the primary symptom, a dark or brown color describes a class of dermatological conditions known as pigmentation disorders. A pigmentation problem causes either a lightening or a darkening of the skin. However, it can limit social contacts and lower quality of life even while it has no effect on physical health. The research focuses on the profits that manufacturers made from the sales of these pharmaceuticals used to treat pigmentation problems. Pigmentation disorder is a long-term, chronic medical condition that results in loss of pigmentation in patches on the skin, hair, eyes, and inside of the mouth. The American Academy of Dermatology refers to vitiligo as a life-altering disorder that can result in low self-esteem, anxiety, and depression.

Key factors driving the growth of the pigmentation disorder treatment market include increase in the number of people suffering from pigmentation disorders is the key factor driving the growth of the market. China, India, and other Asian countries have a large patient pool suffering from pigmentation disorders and this has resulted in the need for effective therapies for pigmentation disorders.

Therefore, high number of research and development initiatives taken by key players such as Reddy’s Laboratories Ltd. and Incyte Corporation drive the growth of the market. Numerous top healthcare companies have flourished in North America region due to the market's favorable conditions; significant market players had developed and launched the medications for pigmentation disorders in order to boost sales and satisfy customer demand for high-end medications.

Moreover, increase in the number of research activities for development of pigmentation disorder and presence of well-established healthcare facilities coupled with rise in demand for advanced pigmentation disorder therapies, and availability of developed healthcare infrastructure with technological advanced systems are the major factors contributing toward the growth of the pigmentation disorder treatment market.

The market also offers growth opportunities to the key players in the market. The healthcare sector in both developed and emerging economies is growing at significant rate due to the increase in the demand for better healthcare services. In addition, increased government spending on the pharmaceutical and biotechnology sectors in developing nations, the expansion of healthcare infrastructure, and the increase in demand for advanced treatments for pigmentation disorders are all anticipated to boost the market for pigmentation disorder treatments during the forecast period. Thus, rise in healthcare spending is expected to open new opportunities for the expansion of pigmentation disorder treatment market. Furthermore, rise in awareness regarding vitiligo conditions and its treatment in the U.S. and Canada provides the lucrative opportunity to the pigmentation disorder treatment market.

The pigmentation disorder treatment market is segmented into type, treatment, distribution channel, and region. On the basis of type, the market is categorized into vitiligo, melasma and others. The vitiligo segment is further classified as segmental and non-segmental. On the basis of treatment, it is categorized into corticosteroids, calcineurin Inhibitor, and others. On the basis of distribution channel, it is fragmented into hospital pharmacies, drug store & retail pharmacies and online pharmacies. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The key players profiled in the study include Arcutis Biotherapeutics, Inc, Astellas Pharma Inc., Bausch Health Companies Inc, Dermavant Sciences Inc, Dr. Reddy,s Laboratories Ltd, Galderma S.A, Glenmark Pharmaceuticals Limited, Incyte Corporation, Obagi Cosmeceuticals LLC and Viatris Inc. The players in the market have been actively engaged in the adoption various strategies such as product approval, and collaboration to remain competitive and gain advantage over the competitors in the market. For instance, in September 2021, Alphatec Holdings, Inc. announced the launch of its product InVictus OsseoScrew Expandable Spine Fixation System.

Key Market Insights

• By type, the vitiligo segment was the largest revenue contributor to the market in 2021 and is estimated to reach $643.0 million by 2031, with a highest CAGR o.
• By treatment, the corticosteroids segment dominated the global market in 2021 and is expected to witness highest CAGR during the forecast period.
• Based on distribution channel, the drug store and retail pharmacies segment was the largest revenue contributor to the market in 2021 with a CAGR of 5.1% during the forecast period. However, the online pharmacies segment is expected to be the fastest-growing segment with a highest CAGR during the forecast period.
• Based on region, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period

Companies Mentioned

• Arcutis Biotherapeutics
• Astellas Pharma Inc.
• Bausch Health Companies Inc.
• Incyte Corporation
• Dermavant Science Inc.
• Viatirs Inc. (Mylan N.V.)
• Galderma SA
• Obagi Cosmeceuticals LLC
• Dr. Reddy's Laboratories Limited
• Glenmark Pharmaceuticals Ltd

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

• Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
• Scientific and technical writings for product information and related preemptions
• Regional government and statistical databases for macro analysis
• Authentic news articles and other related releases for market evaluation
• Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.